NCT04810091 2026-03-09
Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
Clinical Trials
8 trialsNCT03910387 2025-12-16
Telotristat Ethyl to Promote Weight Stability in Patients With Advanced Stage Pancreatic Cancer
Emory University
Phase 2 Completed
NCT03453489 2025-04-10
AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT04543955 2023-06-27
Telotristat With Lutathera in Neuroendocrine Tumors
University of Kentucky
Phase 2 Terminated
NCT04713202 2023-02-10
NET-PACS
Big Ten Cancer Research Consortium
Phase 2 Withdrawn
NCT04672876 2021-12-17
Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors
University of Chicago
Phase 2 Withdrawn
NCT04776876 2021-09-29
Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04034745 2020-12-30
Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain
Cedars-Sinai Medical Center
Withdrawn